Niquille Anne, Bugnon Olivier
School of pharmaceutical sciences, University of Geneva, University of Lausanne, Community Pharmacy, Pharmacie de la PMU, 44 Rue du Bugnon, 1011 Lausanne, Switzerland.
Pharm World Sci. 2010 Aug;32(4):512-9. doi: 10.1007/s11096-010-9401-1. Epub 2010 Jun 5.
To describe drug-related problems (DRPs) and expense problems (EPs) identified by a standardised community pharmacist-based medication review (MR) program among Swiss cardiovascular outpatients (56-75 years old) and to evaluate the need for collaborative pharmacy practice to achieve economic, clinical and humanistic outcomes.
A pilot population of 85 cardiovascular outpatients who were customers of 14 community pharmacies (members of the pharmacieplus virtual chain) and insured with Groupe Mutuel health insurance.
Cross-sectional study of a structured medication review program, conducted by 11 pharmacists in collaboration with 61 general practitioners (GPs), with patient interviews and access to medical data.
Numbers and types of DRPs and EPs within the study population and odds ratios between them, as well as economic, clinical and humanistic outcomes.
Of the included patients, 91% had at least one DRP or EP. The odds ratios indicated that not being exposed to DRPs was associated with a higher chance of reaching the clinical target (OR: 3.4; IC95%:1.1-10.5; P = 0.01), of having a better physical quality of life than the median (OR: 2.5; IC95%: 0.9-7.3; P = 0.05) and having lower total health care costs (OR: 3.2; IC95%:1.1-9.8; P = 0.02).
This cross-sectional study shows that the control of cardiovascular risk factors, quality of life and healthcare costs are statistically related to the presence of DRPs detected by a community pharmacist-based MR program.
描述在瑞士心血管门诊患者（56 - 75岁）中，基于社区药师的标准化药物审查（MR）项目所识别出的药物相关问题（DRP）和费用问题（EP），并评估为实现经济、临床和人文结局而开展协作药学实践的必要性。
选取85名心血管门诊患者作为试点人群，他们是14家社区药房（pharmacieplus虚拟连锁成员）的顾客，并参保于Groupe Mutuel医疗保险。
一项由11名药剂师与61名全科医生（GP）合作开展的结构化药物审查项目的横断面研究，包括患者访谈和获取医疗数据。
研究人群中DRP和EP的数量及类型、它们之间的比值比，以及经济、临床和人文结局。
纳入的患者中，91%至少存在一个DRP或EP。比值比表明，未出现DRP与达到临床目标的更高几率相关（OR：3.4；95%置信区间：1.1 - 10.5；P = 0.01），与身体生活质量优于中位数相关（OR：2.5；95%置信区间：0.9 - 7.3；P = 0.05），且与总医疗费用较低相关（OR：3.2；95%置信区间：1.1 - 9.8；P = 0.02）。
这项横断面研究表明，心血管危险因素的控制、生活质量和医疗费用在统计学上与基于社区药师的MR项目所检测到的DRP的存在相关。
